Gilead announced today (6/22) that its expectation for supply of remdesivir increased from 1 million to exceed 2 million by the end of 2020. Remdesivir is on the forefront of fighting the pandemic, helping shorten the length of hospital recovery times for those afflicted with COVID-19 and then treated with the drug. The company also announced that it was planning on starting trials in August for an easier use, inhalation version of remdesivir, which as of now is only administered intravenously. “We will continue to collaborate globally to ensure sufficient worldwide supply,” Gilead Chief Executive Officer Daniel O’Day said in a statement. 
 
Read more here.  

More on: